Literature DB >> 20038613

Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.

Florence Chapeland-Leclerc1, Christophe Hennequin, Nicolas Papon, Thierry Noël, Aurélie Girard, Gérard Socié, Patricia Ribaud, Claire Lacroix.   

Abstract

We describe the acquisition of flucytosine, azole, and caspofungin resistance in sequential Candida glabrata bloodstream isolates collected from a bone marrow transplant patient with clinical failure. Point mutations in C. glabrata FUR1 (CgFUR1) and CgFKS2 and overexpression of CgCDR1 and CgCDR2 were observed in resistant isolates.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20038613      PMCID： PMC2826023          DOI： 10.1128/AAC.01138-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance.

Authors:  Nicolas Papon; Thierry Noël; Martine Florent; Stéphanie Gibot-Leclerc; Dorothée Jean; Christiane Chastin; Jean Villard; Florence Chapeland-Leclerc
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

Review 3.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

4.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae.

Authors:  Florence Chapeland-Leclerc; Julien Bouchoux; Abdelhak Goumar; Christiane Chastin; Jean Villard; Thierry Noël
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance.

Authors:  Maurizio Sanguinetti; Brunella Posteraro; Barbara Fiori; Stefania Ranno; Riccardo Torelli; Giovanni Fadda
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

8.  Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia.

Authors:  Jong Hee Shin; Myung Jong Chae; Jeong Won Song; Sook-In Jung; Duck Cho; Seung Jung Kee; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  J Clin Microbiol       Date:  2007-06-20       Impact factor: 5.948

9.  Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; J F Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

10.  In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; R J Hollis; C Rice; S Tendolkar; D J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2004-03       Impact factor: 2.803
View more
  38 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

Review 3.  Are the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their Accuracy.

Authors:  Brunella Posteraro; Ljupcho Efremov; Emanuele Leoncini; Rosarita Amore; Patrizia Posteraro; Walter Ricciardi; Maurizio Sanguinetti
Journal:  J Clin Microbiol       Date:  2015-05-20       Impact factor: 5.948

Review 4.  Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?

Authors:  Danièle Maubon; Cécile Garnaud; Thierry Calandra; Dominique Sanglard; Muriel Cornet
Journal:  Intensive Care Med       Date:  2014-08-05       Impact factor: 17.440

5.  Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance.

Authors:  Chayanika Biswas; Sharon C-A Chen; Catriona Halliday; Elena Martinez; Rebecca J Rockett; Qinning Wang; Verlaine J Timms; Rajat Dhakal; Rosemarie Sadsad; Karina J Kennedy; Geoffrey Playford; Deborah J Marriott; Monica A Slavin; Tania C Sorrell; Vitali Sintchenko
Journal:  J Vis Exp       Date:  2017-12-28       Impact factor: 1.355

6.  Acquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.

Authors:  Sandra A Asner; Stefano Giulieri; Manuel Diezi; Oscar Marchetti; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

7.  Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Authors:  María Teresa Durán-Valle; Sara Gago; Alicia Gómez-López; Manuel Cuenca-Estrella; Leticia Jiménez Díez-Canseco; José Luis Gómez-Garcés; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

Review 8.  The Candida pathogenic species complex.

Authors:  Siobhán A Turner; Geraldine Butler
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

9.  Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.

Authors:  Claire M Hull; Josie E Parker; Oliver Bader; Michael Weig; Uwe Gross; Andrew G S Warrilow; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

10.  Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009.

Authors:  Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.